Novoic
Entrepreneur First '19London, GB · Founded 2019 · 3 known investors
Find your way into Novoic
853 people in our graph share verified history with the Novoic team — schools, employers, funds. One of them is your warm intro.
Novoic develops AI-based software that analyzes speech to detect mild cognitive impairment and early-stage Alzheimer's disease, aiming to enable earlier detection. Its products—including automated speech-based cognitive testing (Storyteller), a screening management dashboard, and a speech-processing API—are used by medical centers and research institutions, primarily in the US.
Also known as Storyteller by Novoic
Founders & leadership
Novoic was founded in 2019 by Emil Fristed and Jack Anthony Weston.
Investors · 3
Company profile
researched Aug 2026Novoic develops AI-enabled software that detects subtle cognitive impairment and Alzheimer's neuropathology from how people speak. Its assessment can be completed in about 10 minutes and runs in a browser on any standard smartphone, tablet or computer, avoiding the need to distribute dedicated devices. The company describes itself as an Oxford-founded, clinical-stage digital medtech company developing clinical deep learning algorithms to detect early-stage neurological disease from speech.
The product line comprises three components. Storyteller is a fully automated, audio-verbal speech-based cognitive test built around the Automated Story Recall Task (ASRT), in which participants are played pre-recorded short stories and asked to recall them; the spoken responses are analysed for episodic memory function and language use. The Novoic Dashboard manages digital screening and monitoring at scale, offering AI-assisted triage that is configurable from fully manual to fully automated, patient-funnel analytics and forecasting, and deployment via SDKs or hosted versions for large multi-site trials. A Speech API exposes the underlying speech processing, automated speech recognition, automated quality control and AI-based speech biomarkers for customers who prefer to build their own applications.
The company emphasises data integrity and compliance, citing built-in quality control systems, audio standardisation, state-of-the-art automated speech recognition, HIPAA/GDPR compliance, automated backups and a digitally native quality management system aligned to evolving medical software quality standards.
Founding story
Novoic is described in company materials as an Oxford-founded clinical-stage digital medtech company. Emil Fristed is identified as CEO and Dr. Jack Weston as CTO.
Business model
Novoic sells software to research and clinical organisations: an automated speech-based cognitive testing product (Storyteller), a screening/monitoring dashboard, and a speech-processing API. Storyteller and the accompanying automated AI-based analysis are stated to be available for researchers and for commercial use from Novoic. Deployment options include SDKs and hosted versions, supporting large multi-site trials.
Traction
The company states its algorithms are used by more than 50 institutions, and that automated assessments and analysis outputs inform patient selection in over 50 US medical centers. Its Storyteller system was selected as the digital screener for the fourth generation of the Alzheimer's Disease Neuroimaging Initiative (ADNI4), where it is intended to support online screening of 20,000 patients across more than 50 sites. Two Novoic-run AMYPRED clinical trials in the UK and US (NCT04828122, NCT04928976) were completed and published in Brain Communications in October 2022.
Latest developments
Novoic's website describes ongoing support for early detection in underserved communities across more than 50 medical centers together with the Alzheimer's Disease Neuroimaging Initiative, and markets three products: Storyteller, the Dashboard and the Speech API. The most recent dated source event is the October 2022 publication of the AMYPRED trial results and the subsequent US rollout including ADNI4.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Novoic positions its offering as a scalable alternative or complement to costly amyloid PET scans and to long, in-person pen-and-paper cognitive tests. It states its speech-based tests were the first to successfully predict amyloid PET positivity, with performance described as comparable to plasma tests, and that its AMYPRED studies were the first to test deep speech phenotyping in biomarker-confirmed early-stage Alzheimer's disease. The company frames early detection access as a bottleneck, stating that fewer than 1% of people have access today.
Novoic cites fully automated, browser-based self-assessment usable on any smart device and tested on thousands of users; low burden and usability in elderly and cognitively impaired populations; custom in-house audio and language models rather than off-the-shelf foundation models; and clinical validation in biomarker-confirmed preclinical and prodromal Alzheimer's disease, where its speech-based system outperformed the PACC5 composite in predicting amyloid status.
Technology
Novoic designs and trains large audio and language models in-house using proprietary methods and datasets, targeting sensitivity to clinically relevant patterns. The company states that traditional speech statistics and off-the-shelf foundation models such as BERT derivatives were insufficient at clinical-research dataset sizes, so it built a custom deep learning model for evaluating text pairs, drawing on clinical neuroscience and large language model research, to assess the quality, content and form of spoken story-recall responses. The stack also includes automated speech recognition, audio standardisation and automated quality control, delivered through a browser-based interface.
Go-to-market
Novoic works with research consortia and academic institutions, most prominently the Alzheimer's Disease Neuroimaging Initiative, and sells directly to medical centers and trial sponsors. Its assessments and rapid analysis outputs inform patient selection at more than 50 US medical centers. Peer-reviewed clinical publications and its own clinical trials serve as validation-led marketing.
Medical centers, clinical research sites and organisations running Alzheimer's disease trials and screening programmes, including large multi-site studies; researchers and commercial users of speech-based cognitive assessment; developers accessing capabilities via API.
Geography
Headquartered in London (internal record) and described as Oxford-founded. Clinical trials were run in the UK and the US, and deployment is concentrated in the US, where over 50 medical centers use the assessments.
History
Novoic ran the AMYPRED clinical studies in the UK and the US, with results published in Brain Communications on 17 October 2022 in collaboration with researchers from Harvard Medical School and Strategic Global R&D. Following publication, the system began rolling out across the US, including selection as the digital screener for ADNI4. Novoic is listed as an Entrepreneurs First portfolio company.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsResults from two Novoic-run clinical trials in the UK and US (NCT04828122, NCT04928976) were published in Brain Communications, showing that brain amyloid presence or absence can be detected at preclinical and prodromal Alzheimer's stages via AI-based speech analysis, outperforming the PACC5 composite. Research was conducted with Harvard Medical School and Strategic Global R&D.
Novoic's Storyteller system is being rolled out across the US as the digital screener for the fourth generation of the Alzheimer's Disease Neuroimaging Initiative (ADNI4), supporting online screening of 20,000 patients across more than 50 sites.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 6
primary sources listed
- Novoicnovoic.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Novoic do?
- Novoic builds AI speech-analysis software that detects early-stage Alzheimer's disease and cognitive impairment.
- Who founded Novoic?
- Novoic was founded by Emil Fristed, Jack Anthony Weston in 2019.
- Who are Novoic's investors?
- Novoic's investors include Anthemis Venture, Entrepreneur First, Mana Ventures.
- Where is Novoic headquartered?
- Novoic is headquartered in London, GB.